Condition: Alopecia Areata · Sponsor: Sun Pharma Japan Limited
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Study Site 102 | Asahikawa, Japan | Not Yet Recruiting |
| Study Site 117 | Bunkyō City, Japan | Not Yet Recruiting |
| Study Site 119 | Ebina, Japan | Not Yet Recruiting |
| Study Site 101 | Hamamatsu, Japan | Not Yet Recruiting |
| Study Site 116 | Ishikawa, Japan | Not Yet Recruiting |
| Study Site 112 | Kitakyushu, Japan | Not Yet Recruiting |
| Study Site 118 | Kōtoku, Japan | Not Yet Recruiting |
| Study Site 110 | Kurashiki, Japan | Not Yet Recruiting |
| Study Site 113 | Kurume, Japan | Not Yet Recruiting |
| Study Site 107 | Kyoto, Japan | Not Yet Recruiting |
| Study Site 106 | Mitaka-shi, Japan | Recruiting |
| Study Site 114 | Miyagi-gun, Japan | Not Yet Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07617597